Advanced search×

Adverse events during the Scleroderma Lung Study.

Daniel E DE Furst, Chi-Hong CH Tseng, Philip J PJ Clements, Charlie C Strange, Donald P DP Tashkin, Michael D MD Roth, Dinesh D Khanna, Ning N Li, Robert R Elashoff, Dean E DE Schraufnagel, and

Am J Med 124(5):459-67 (2011) PMID 21531236

The Scleroderma Lung Study (SLS) was a 1-year, randomized, controlled trial of oral cyclophosphamide for scleroderma-related pulmonary alveolitis. It concluded that oral cyclophosphamide slowed the decline in the forced vital capacity (% predicted) and had a beneficial effect on dyspnea, skin changes, and several quality of life measures of systemic sclerosis. We now report an in-depth assessment of the toxicity of cyclophosphamide during the year of therapy and the year after therapy was completed, during which time the investigators were still masked to the treatment assignment.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.amjmed.2010.12.009
Version: za2963e q8za9 q8zbb q8zc9 q8zd3 q8ze3 q8zf3 q8zg7

Similar articles you may find interesting…

  1. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials.
    Fausto F Petrelli, Karen K Borgonovo, ... Sandro S Barni

    Anticancer Drugs 22(2):128-35 (2011) PMID 21218604

    The aim of this meta analysis was to evaluate the benefit of adding concomitant trastuzumab to neoadjuvant(anthracycline and taxane-based) chemotherapy, which was assessed based on two published randomized controlled trials. The eligible patients were randomized to receive either neoadjuvant chemoth...
  2. Identification of influenza A pandemic (H1N1) 2009 variants during the first 2009 influenza outbreak in Mexico City
    Hector M Zepeda, Lizbeth Perea-Araujo, ... Ricardo J García-Cavazos

    J Clin Virol 48(1):4 (2010) PMID 20226730

    We have provided a baseline of epidemiological data from the first outbreak of influenza A pH1N1 (2009) during 1-5 May in Mexico City. The sequencing of partial fragments of the HA and NA genes did not show the presence of previously described mutations affecting known sites of antiviral resistance...
  3. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-bl...
    M Dougados, J Braun, ... I Logeart

    Ann Rheum Dis 70(5):799-804 (2011) PMID 21317434 PMCID PMC3070274

    /st> ETN has short-term efficacy for patients with advanced AS, as was previously reported for less advanced disease. The efficacy is observed for the main symptoms (pain) and on markers of inflammation (CRP), as well as disease severity in terms of spinal mobility and pulmonary function....
    View PDF